Neural Regeneration Research ›› 2025, Vol. 20 ›› Issue (8): 2309-2310.doi: 10.4103/NRR.NRR-D-24-00545

Previous Articles     Next Articles

In vivo direct neuronal conversion as a therapeutic strategy for ischemic stroke

Takashi Irie, Taito Matsuda*   

  1. Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan (Irie T, Matsuda T) Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan (Irie T)
  • Online:2025-08-15 Published:2024-12-13
  • Contact: Taito Matsuda, PhD, matsuda.taito.344@m.kyushu-u.ac.jp.
  • Supported by:
    This work was supported by JSPS KAKENHI Grant Number JP24K18622 (to TI), and JSPS KAKENHI Grant Number JP23K18451 (to TM). We thank N. Isobe and K. Nakashima (Kyushu University, Japan) for discussions; Y. Nakagawa (Kyushu University, Japan) for excellent secretarial assistance; N.Elizabeth (Kyushu University, Japan) for proofreading the manuscript.

PDF

5

Abstract: Stroke causes neuronal loss, which ultimately results in persistent neurological dysfunction. Globally, stroke was the third-leading cause of death and disability combined in all ages in 2019, after neonatal disorders and ischemic heart disease. In that year, there were 12.2 million incident strokes, 101 million prevalent strokes, and 143 million disability-adjusted life-years due to stroke. Ischemic stroke constituted 62.4% of all incident strokes in 2019, and showed smaller reductions in age-standardized rates from 1990 to 2019 than intracerebral hemorrhage and subarachnoid hemorrhage (GBD 2019 Stroke Collaborators, 2021). To date, clinical treatments for the hyperacute phase of ischemic stroke are improving, but treatments for subsequent phases remain limited.